Altered NFE2 activity predisposes to leukemic transformation and myelosarcoma with AML-specific aberrations.
Jutzi JS, Basu T, Pellmann M, Kaiser S, Steinemann D, Sanders MA, Hinai ASA, Zeilemaker A, Bojtine Kovacs S, Koellerer C, Ostendorp J, Aumann K, Wang W, Raffoux E, Cassinat B, Bullinger L, Schlegelberger B, Valk PJM, Pahl HL.
Jutzi JS, et al. Among authors: koellerer c.
Blood. 2019 Apr 18;133(16):1766-1777. doi: 10.1182/blood-2018-09-875047. Epub 2019 Feb 12.
Blood. 2019.
PMID: 30755419
Free PMC article.